

# Bordetella

Friday, September 19, 2025 6:10 PM

## Bordetella pertussis (Whooping Cough)

### Important Properties

- Morphology: Small, coccobacillary, encapsulated, Gram-negative rod.
- Host: Humans only.
- Transmission: Airborne droplets during severe coughing episodes.

### Pathogenesis & Epidemiology

- Attachment:
  - Binds to ciliated epithelial cells of the upper respiratory tract (does not invade tissue).
  - Mediated by filamentous hemagglutinin (FHA) on pili.
  - Antibody against FHA → blocks attachment → protection.

- Key Virulence Factors:

1. Pertussis toxin (A-B toxin)

- Catalyzes ADP-ribosylation of Gi protein → inhibits Gi → unopposed adenylate cyclase activity.
- ↑ cAMP → edema of respiratory mucosa → severe cough.
- Also causes lymphocytosis by preventing lymphocyte migration into lymphoid tissue.

2. Adenylate cyclase enzyme

- Produced by bacteria, taken up by neutrophils → inhibits phagocytosis.
- Mutants lacking cyclase activity = avirulent.

3. Tracheal cytotoxin

- Fragment of peptidoglycan.
- Damages ciliated epithelial cells.
- Acts with endotoxin to induce nitric oxide → kills cilia.

- Epidemiology:

- Primarily in infants & young children 🧒.
- Highly contagious.
- Declined due to vaccines but periodic outbreaks occur due to waning immunity.

## 🔄 Flow of Pathogenesis

### Inhalation of droplets

- Attachment to ciliated epithelium (via FHA)
- Pertussis toxin → ↑ cAMP → edema + lymphocytosis
  - Adenylate cyclase → ↓ neutrophil activity
- Tracheal cytotoxin + endotoxin → ciliary death
- Persistent severe cough (whooping cough)

## 📖 Clinical Findings

- Early phase: Mild upper respiratory tract infection.
- Paroxysmal phase (1-4 weeks):
  - Severe paroxysmal cough → repeated hacking coughs + copious mucus.
  - Followed by inspiratory "whoop" (due to narrowed

glottis).

- Leukocytosis: up to 70% lymphocytes.
- Organism remains localized to respiratory tract  
→ blood cultures negative.

- Complications:

- CNS anoxia, exhaustion due to coughing.
- Pneumonia → main cause of death.

- Adults:

- "100-day cough" (chronic paroxysmal cough).
- Whoop often absent → underdiagnosed.

 Table: Clinical Course of Pertussis

| Stage              | Duration     | Features   |
|--------------------|--------------|--|
| Catarrhal stage    | 1-2 weeks    | Mild URTI, highly contagious                     |
| Paroxysmal stage   | 1-4 weeks    | Severe coughing fits, inspiratory "whoop," mucus |
| Convalescent stage | Weeks-months | Gradual recovery, cough may persist              |



## Laboratory Diagnosis

- Specimen: Nasopharyngeal swab (best during paroxysmal stage).
- Culture:
  - Medium: Bordet-Gengou agar (20–30% blood → inactivates inhibitors).
  - Growth: Slow → limits routine diagnosis.
- Identification:
  - Agglutination with specific antiserum.
  - Fluorescent antibody staining.
- Rapid Tests:
  - PCR → rapid, specific, highly sensitive ✓.
  - Direct fluorescent antibody staining on swab.
- Serology: Antibody detection in patients with prolonged

cough.

- Limitation: Isolation difficult in late disease.

### Flow of Diagnosis

Nasopharyngeal swab

→ Bordet-Gengou culture (slow) OR Fluorescent antibody staining

→ PCR (preferred, rapid & sensitive)

→ If prolonged cough → Serology for antibodies

---

### Treatment


- Drug of choice: Azithromycin (a macrolide).
  - Reduces organisms in throat → ↓ transmission & complications.
  - Little effect once mucosal damage has occurred (prolonged cough stage).

- Supportive care (esp. in infants):

- Oxygen therapy
- Mucus suction

## Prevention

### I. Vaccines

- Acellular pertussis vaccine (aP)  (currently used in US):

#### ▶ Contains 5 antigens:

- Pertussis toxoid (genetically inactivated toxin)
- Filamentous hemagglutinin (FHA)
- Pertactin
- Fimbriae types 2 & 3

- Advantages: Fewer side effects.
- Disadvantage: Shorter duration of immunity.

- Killed whole-cell vaccine  (no longer used in US):

- Still used in some countries.
- Associated with side effects (rare encephalopathy)


≈ 1/million doses).

## 2. Immunization Schedule

- DTaP (Diphtheria, Tetanus, acellular Pertussis):
  - 3 primary doses beginning at 2 months.
  - Booster: 12-15 months.
  - Booster: At school entry.
- Adolescents: Booster (10-18 years) → Boostrix or Adacel (contain diphtheria & tetanus toxoids too).
- Adults: Pertussis booster recommended.
- Pregnant women: Should be vaccinated → maternal IgG crosses placenta → protects newborn 🧒.

## 3. Post-Exposure Prophylaxis

- Azithromycin:
  - For exposed, unimmunized individuals.
  - Also for exposed immunized children <4 years (since vaccine immunity is incomplete).

 Table: Prevention Strategies for Pertussis



| Strategy       | Details   |
|----------------|---|
| Vaccine        | Acellular vaccine (aP) – 5 antigens                                     |
| Schedule       | Primary (2 mo), Booster (12-15 mo), School entry, Teen & adult boosters |
| Pregnant women | Vaccination → maternal IgG → protects newborn                           |
| Post-exposure  | Azithromycin for exposed (unimmunized or partially immunized children)  |